Paradigm shift in activity assessment of IgA nephropathy – optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting

Bibliography

• Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 2008;118:629-39
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011;22:1795-803
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013;368:2402-14
   PubMed Web of Science ®Google Scholar
• D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000;36:227-37
   PubMed Web of Science ®Google Scholar
• Chauveau D, Droz D. Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 1993;104:1-5
   PubMedGoogle Scholar
• Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110:434-7
   PubMed Web of Science ®Google Scholar
• Shen P, He L, Li Y, et al. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract 2007;106:c157-61
   PubMed Web of Science ®Google Scholar
• Imai H, Miura N. A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol 2011;16:195-201
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Yokoyama H, Sato H, et al. Japan renal biopsy registry and Japan kidney disease registry: committee report for 2009 and 2010. Clin Exp Nephrol 2013;17:155-73
   PubMed Web of Science ®Google Scholar
• Manno C, Strippoli GF, D’Altri C, et al. A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kid Dis 2007;49:763-75
   PubMed Web of Science ®Google Scholar
• Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159-66
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468-74
   PubMed Web of Science ®Google Scholar
• Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 2008;31:433-41
   PubMed Web of Science ®Google Scholar
• Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004;15:157-63
   PubMed Web of Science ®Google Scholar
• Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006;47:751-60
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012;82:840-56
   PubMed Web of Science ®Google Scholar
• Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2013. Clin Exp Nephrol 2014;18:346-423
   Web of Science ®Google Scholar
• Donadio JV, Grande JP. IgA Nephropathy. N Engl J Med 2002;347:738-48
   PubMed Web of Science ®Google Scholar
• Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 2006;69:1455-8
   PubMed Web of Science ®Google Scholar
• Lee HS, Lee MS, Lee SM, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee’s glomerular grading system. Nephrol Dial Transplant 2005;20:342-8
   PubMed Web of Science ®Google Scholar
• Coppo R. Tonsillectomy as a treatment for IgA nephropathy: an old-fashioned story or still a feasible choice? NDT-EDUCATIONAL 2014. Available from: www.ndt-educational.org/blog-253-15
   Google Scholar
• Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol 1999;51:147-52
   PubMed Web of Science ®Google Scholar
• Piccoli A, Codognotto M, Tabbi MG, et al. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 2010;25:2583-9
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen X, Nishi S, et al. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 2004;65:1135-44
   PubMed Web of Science ®Google Scholar
• Chen Y, Tang Z, Wang Q, et al. Long-term efficacy of tonsillectomy in Chinese patients with IgA nephropathy. Am J Nephrol 2007;27:170-5
   PubMed Web of Science ®Google Scholar
• Maeda I, Hayashi T, Sato KK, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrol Dial Transplant 2012;27:2806-13
   PubMed Web of Science ®Google Scholar
• Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980;66:1432-6
   PubMed Web of Science ®Google Scholar
• Mattu TS, Pleass RJ, Willis AC, et al. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem 1998;273:2260-72
   PubMed Web of Science ®Google Scholar
• Renfrow MB, Cooper HJ, Tomana M, et al. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 2005;280:19136-45
   PubMed Web of Science ®Google Scholar
• Renfrow MB, Mackay CL, Chalmers MJ, et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry. Implications for IgA nephropathy. Anal Bioanal Chem 2007;389:1397-407
   PubMed Web of Science ®Google Scholar
• Takahashi K, Wall SB, Suzuki H, et al. Clustered O-glycans of IgA1. Defining macro- and micro-heterogeneity by use of electron capture/transfer dissociation. Mol Cell Proteomics 2010;9:2545-57
   PubMed Web of Science ®Google Scholar
• Takahashi K, Smith AD, Poulsen K, et al. Identification of structural isomers in IgA1 hinge-region O-glycosylation using high-resolution mass spectrometry. J Proteome Res 2012;11:692-702
   PubMed Web of Science ®Google Scholar
• Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100:470-4
   PubMed Web of Science ®Google Scholar
• Mestecky J, Tomana M, Crowley-Nowick PA, et al. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol 1993;104:172-82
   PubMedGoogle Scholar
• Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997;52:509-16
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Wyatt RJ, Lee J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007;71:1148-54
   PubMed Web of Science ®Google Scholar
• Raska M, Moldoveanu Z, Suzuki H, et al. Identification and characterization of CMP-NeuAc:GalNAc-IgA1 α2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 2007;369:69-78
   PubMed Web of Science ®Google Scholar
• Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 2008;19:1008-14
   PubMed Web of Science ®Google Scholar
• Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem 2014;289:5330-9
   PubMed Web of Science ®Google Scholar
• Glassock RJ. The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens 2011;20:153-60
   PubMed Web of Science ®Google Scholar
• Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 2014;9:e98081
   PubMedGoogle Scholar
• Allen AC, Bailey EM, Brenchley PE, et al. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation. Observations in three patients. Kidney Int 2001;60:969-73
   PubMed Web of Science ®Google Scholar
• Hiki Y, Odani H, Takahashi M, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001;59:1077-85
   PubMed Web of Science ®Google Scholar
• Novak J, Tomana M, Matousovic K, et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005;67:504-13
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fun R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119:1668-77
   PubMed Web of Science ®Google Scholar
• Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999;104:73-81
   PubMed Web of Science ®Google Scholar
• Novak J, Julian BA, Mestecky J, Renfrow MB. Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 2012;34:365-82
   PubMed Web of Science ®Google Scholar
• Camilla R, Suzuki H, Daprà V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011;6:1903-11
   PubMed Web of Science ®Google Scholar
• Gómez-Guerrero C, López-Armada MJ, González E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-α and IL-6, and proliferation. J Immunol 1994;153:5247-55
   PubMed Web of Science ®Google Scholar
• Tamouza H, Chemouny JM, Raskova Kafkova L, et al. IgA1 immune complex-mediated activation of MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int 2012;82:1284-96
   PubMed Web of Science ®Google Scholar
• Novak J, Raskova Kafkova L, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured mesangial cells. Nephrol Dial Transplant 2011;26:3451-7
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangial-derived TNF-α. Glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008;294:F945-55
   PubMed Web of Science ®Google Scholar
• Lai KN, Leung JC, Chan LY, et al. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 2009;24:62-72
   PubMed Web of Science ®Google Scholar
• Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012;82:790-6
   PubMed Web of Science ®Google Scholar
• Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;2:1579-87
   Google Scholar
• Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One 2014;9:e89707
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Matsuzaki K, Suzuki H, et al. Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol 2014;18:770-7
   PubMed Web of Science ®Google Scholar
• Shirato K, Nakajima K, Korekane H, et al. Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle. J Clin Biochem Nutr 2011;48:20-5
   PubMed Web of Science ®Google Scholar
• Yoshizumi S, Suzuki S, Hirai M, et al. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metabolism 2007;56:420-9
   PubMed Web of Science ®Google Scholar
• Rudd PM, Elliott T, Cresswell P, et al. Glycosylation and the immune system. Science 2001;291:2370-6
   PubMed Web of Science ®Google Scholar
• Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 2004;65:1544-7
   PubMed Web of Science ®Google Scholar
• Altmann F. The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2006;142:99-115
   PubMed Web of Science ®Google Scholar
• Kato Y, Kaneko MK. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014;4:1-9
   Google Scholar
• Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803-8
   PubMed Web of Science ®Google Scholar
• Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008;8:3257-62
   PubMed Web of Science ®Google Scholar
• Laitinen L, Juusela H, Virtanen I. Binding of the blood group-reactive lectins to human adult kidney specimens. Anat Rec 1990;226:10-17
   PubMedGoogle Scholar
• Franc V, Řehulka P, Raus M, et al. Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J Proteomics 2013;92:299-312
   PubMed Web of Science ®Google Scholar
• Sakai K, Shimizu Y, Chiba T, et al. Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies. Biochemistry 2007;46:253-62
   PubMed Web of Science ®Google Scholar
• Yuasa N, Zhang W, Goto T, et al. Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression. J Biol Chem 2010;285:30587-97
   PubMed Web of Science ®Google Scholar
• Moore JS, Kulhavy R, Tomana M, et al. Reactivities of N-acetylgalactosamine-specific lectins with human IgA1 proteins. Mol Immunol 2007;44:2598-604
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suzuki H, Yasutake J. Serum galactose-deficient IgA1 detected by specific monoclonal antibody KM55 is increased in IgA nephropathy patients. American Society of Nephrology Annual Meeting. 2014. TH-PO372
   Google Scholar